BC Extra | Oct 2, 2019
Company News

Imaging company Lantheus enters therapeutics with Progenics takeout

Lantheus plans to acquire Progenics in an all-stock deal, creating a path for the medical imaging company to move into therapeutics. Based on the 86.4 million outstanding shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) and the...
BC Extra | Jun 22, 2019
Clinical News

June 21 Clinical Quick Takes: Melanoma miss for Exelixis/Genentech combo; plus Progenics, Turning Point, Gracell

Cotellic/Tecentriq combo misses in melanoma  Exelixis Inc. (NASDAQ:EXEL) revealed in a Thursday SEC filing that Cotellic cobimetinib plus Tecentriq atezolizumab from partner Genentech Inc. missed the primary endpoint of improving progression-free survival vs. Keytruda pembrolizumab...
BioCentury | Oct 6, 2018
Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
BC Week In Review | Aug 10, 2018
Financial News

Zogenix, Progenics raise follow-ons

Zogenix Inc. (NASDAQ:ZGNX) and Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) each priced follow-on offerings late Aug. 7th. Zogenix raised $312 million through the sale of 6 million shares at $52 in an offering underwritten by BofA Merrill...
BC Extra | Aug 8, 2018
Financial News

Zogenix, Progenics raise follow-ons

Zogenix Inc. (NASDAQ:ZGNX) and Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) each priced follow-on offerings late Tuesday. Zogenix raised $312 million through the sale of 6 million shares at $52 in an offering underwritten by BofA Merrill Lynch,...
BC Week In Review | Aug 3, 2018
Clinical News

Progenics' Azedra wins FDA nod for rare NETs

FDA approved Azedra iobenguane I 131 from Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) to treat unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma. The agency said Azedra is the first drug it has approved for the rare...
BC Extra | Jul 30, 2018
Company News

Progenics' Azedra wins FDA nod for rare NETs

FDA approved Azedra iobenguane I 131 from Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) to treat unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma. The agency said Azedra is the first drug it has approved for the rare...
BioCentury | Apr 6, 2018
Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
BC Week In Review | Mar 30, 2018
Clinical News

FDA extends review of Progenics' Azedra

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) said FDA will extend its review of an NDA for Azedra iobenguane I 131, postponing its PDUFA date to July 30 from April 30. The therapy is under Priority Review to...
BC Extra | Mar 23, 2018
Company News

FDA extends review of Progenics' Azedra

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) slipped $0.82 (10%) to $7.54 on Friday after it said FDA will extend its review of an NDA for Azedra iobenguane I 131, postponing its PDUFA date to July 30 from...
Items per page:
1 - 10 of 38